Evidence map›Paper›PMID 40100602›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Mass Cytometry Immunophenotyping of Graft-Conditioned Cells Following Major Histocompatibility Complex Mismatched Murine Allograft.

L Angel Ayala, Pauline U Nguyen, Cuiwen Zhou, Gabriella L Hisoire, Alizeh H Ahmedani, Xiyu Chen, Ankita Daud, Abigail Valdovinos, Erika S Varady, Matthew A Inlay and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

L Angel Ayala *Sue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Pauline U Nguyen *Sue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Cuiwen ZhouSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Gabriella L HisoireSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Alizeh H AhmedaniSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Xiyu ChenSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Ankita DaudSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Abigail ValdovinosSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Erika S VaradySue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA.
Matthew A InlaySue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA. minlay@uci.edu.
Vanessa M ScarfoneSue and Bill Gross Stem Cell Research Center, University of California Irvine, Irvine, CA, USA. vscarfon@hs.uci.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy for a variety of blood disorders but primarily reserved for blood cancer patients due to the life-threatening risk of acute graft-versus-host disease (aGVHD). Development of aGVHD is driven by alloreactive T cells that recognize the recipient's tissues as foreign and initiate a robust immune response causing severe tissue damage of the skin, liver, and gut. While methods to reduce aGVHD incidence and severity exist including posttransplant cyclophosphamide, relapse rates and transplantation-related mortality remain. We previously published a study using graft conditioning with glucocorticoids as a strategy to modify the immune repertoire in the donor grafts prior to transplantation to reduce aGVHD. Here, we describe a protocol to characterize the T-cell response in recipient mice given transplantation of graft-conditioned allogeneic donor cells via mass cytometry. Mass cytometry is a technology that uses heavy metal tags in place of fluorochromes to allow high-dimensional flow cytometric analysis. In this protocol, we include an antibody panel of 39 different antibodies conjugated to 41 different heavy metal tags that have been validated and titrated for barcoding and immunophenotyping by lineage markers, activation markers, cytokine secretion, and transcription factors. This chapter details the graft conditioning, transplantation, processing, barcoding, staining, and mass cytometric analysis of immune cells following murine allo-HCT.

Indexed as

Flow CytometryGraft vs Host DiseaseHematopoietic Stem Cell TransplantationImmunophenotypingMajor Histocompatibility ComplexTransplantation ConditioningAllograftsAnimalsMiceT-LymphocytesTransplantation, HomologousAllogeneic transplantConventional T cellsGraft conditioningGraft-versus-host diseaseMass cytometryRegulatory T cells

Identifiers

PMID40100602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.